Appointment of CFO

Paris, France, and Eastleigh and Manchester, UK - 2 January - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the appointment of Steve Gibson as Chief Financial Officer with immediate effect. Mr Gibson will become a Board Director of the Company, subject to shareholder approval, at the Company's Annual General Meeting.

Steve joined Novacyt in 2017 and has served as Group Finance Director since 2020. Prior to joining Novacyt, Steve spent over 10 years in various finance departments at Hewlett-Packard and then Hewlett Packard Enterprise in positions of increasing seniority. Steve is a Chartered Management Accountant (CIMA) and has more than 18 years of international commercial experience.

Commenting, James Wakefield, Non-Executive Chairman, said: "We are delighted to welcome Steve as our CFO. He has impressed us with his financial and operational expertise and was instrumental in the acquisition of Yourgene Health plc as well as delivering the strategic changes to the Company over the last two years. The Board looks forward to working with him as we continue to execute our growth strategy."

Additional Disclosures Required under the AIM Rules for Companies

Steven Michael Gibson (aged 41) has held the following directorship or partnerships in the past five years:

Lab21 Healthcare Limited Biotec Laboratories Limited Primer Design Limited Microgen Bioproducts Limited Novacyt UK Holdings Limited IT-IS International Limited Delta Diagnostics (UK) Limited Yourgene Health Limited Yourgene Health UK Limited Yourgene Genomic Services Limited Elucigene Limited Yourgene Health Canada Investments Yourgene Health Canada Holdings Yourgene Health Inc

Mr Gibson and persons closely associated (as defined under MAR) with Mr Gibson currently hold 9,116 ordinary shares of €1/15 each in the Company.